NCT01723774View on ClinicalTrials.gov

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

April 10, 2013

Primary Completion Date

April 13, 2021

Study Completion Date

August 24, 2026

Conditions
Breast Neoplasms
Interventions
DRUG

PD0332991

DRUG

Anastrozole

DRUG

Goserelin

PROCEDURE

Surgery (standard of care)

-Breast and axillary lymph node surgery

PROCEDURE

Tumor biopsy

Trial Locations (4)

35233

University of Alabama, Birmingham

55905

Mayo Clinic - Rochester, Rochester

63122

Washington University School of Medicine, St Louis

85259

Mayo Clinic - Scottsdale, Scottsdale

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Washington University School of Medicine

OTHER

NCT01723774 - PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer | Biotech Hunter | Biotech Hunter